TSO3 Inc. (TOS) Appoints Harold R. Tessman As COO

QUÉBEC CITY, Jan. 27, 2016 /PRNewswire/ - TSO3 Inc. (TSX: TOS), a leader in low-temperature medical device sterilization, has appointed Harold R. Tessman to the new position of chief operating officer.

Tessman brings to TSO3 more than 30 years of operational experience at industrial, consumer products and service organizations. His background includes extensive experience in operations, supply chain management, organizational development and M&A, as well as experience in the manufacturing of sterilizers and other medical devices.

"As a proven operational leader at fast-growing international organizations, Harold will be focused on strengthening the manufacturing and quality control systems at our U.S. and Canadian facilities," said TSO3 President and CEO R.M. (Ric) Rumble. "His responsibilities will include the expansion of our manufacturing workforce to meet the increasing demand for our revolutionary STERIZONE® VP4 Sterilizer."

TSO3 recently announced orders from its new global distribution partner, Getinge Infection Control, a world leader in infection control solutions. The level of orders would fulfill the contractual minimums established for the first year of the distribution agreement the partners signed in November for the STERIZONE® VP4 Sterilizer, as well as associated consumables and accessories.

Prior to joining TSO3, Tessman served as managing director and senior consultant for 10 years with TBM Consulting Group, a global operations management consulting firm. At TBM, he was a trusted advisor to Fortune 500 companies, private equity firms, and various multinational companies involved in medical device, pharma and other industries. In particular, Tessman oversaw the start-up phase of a global medical device company's manufacturing plant, including materials management, scheduling, quality assurance and processes related to the production of medical equipment.

Earlier Tessman served in various senior executive operations and supply chain positions in the consumer products industry. He led the execution of several acquisitions and corporate integrations, ranging from under $100 million to more than $5 billion. He began his operations career as the group operations manager and general manager at the Yamazaki Group, where he was trained in 'lean manufacturing.'

Tessman holds an MBA in Finance from Michigan State University and a Bachelor of Arts in International Studies and Economics from James Madison College.

About TSO3

Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes. For more information about TSO3, visit the company's web site at www.tso3.com or contact Liolios Group at 949 574-3860 or email [email protected] or Renmark Financial Communications at 416 644-2020 or 514 939-3989 or by email at [email protected] .

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.